This underscores the continuing unmet need in neoadjuvant treatment for HR-positive, HER2-negative breast cancer, especially when compared with the significantly improved outcomes seen in HER2-positive or triple-negative breast cancer in recent years. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.